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Aims Duchenne muscular dystrophy (DMD) is a severe striated muscle disease due to the absence of dystrophin. Dystro-
phin deficiency results in dysfunctional sodium channels and conduction abnormalities in hearts of mdx mice. Disease
progression in the mdx mouse only modestly reflects that of DMD patients, possibly due to utrophin up-regulation.
Here, we investigated mice deficient in both dystrophin and utrophin [double knockout (DKO)] to assess the role of
utrophin in the regulation of the cardiac sodium channel (Nav1.5) in mdx mice.
Methods
and results
Co-immunoprecipitation studies in HEK293 cells showed that utrophin interacts with Nav1.5 via syntrophin proteins,
an interaction abolished by deletion of the PDZ (PSD-95, Dlg, and Zona occludens) domain-binding motif of Nav1.5.
We also provide evidence for such interaction in mouse heart using Nav1.5 C-terminus fusion proteins. In hearts of
DKO mice, Nav1.5 protein levels were decreased by 25+ 8%, together with a 42+12% reduction of syntrophins
compared with mdx, where utrophin was up-regulated by 52+ 9% compared with C57BL/10 control mice. Sodium
current was found to be reduced by 41+5% in DKO cardiomyocytes compared with mdx, representing a loss of
63+ 3% when compared with C57BL/10 wild-type control mice. Decreased Nav1.5 protein and current in DKO
were reflected in a significant slowing of 27+ 6% of maximal upstroke velocity of the cardiac action potential com-
pared with mdx.
Conclusion Utrophin plays a central role in the regulation of Nav1.5 in mdx mice. These findings provide support for therapeutic
strategies aimed at overexpressing utrophin in the hopes of reducing cardiac pathology in DMD patients.
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1. Introduction
Duchenne muscular dystrophy (DMD) is an X-linked recessive dis-
order affecting 1/3500 males and is currently the most severe dystro-
phinopathy.1 The disease results from the absence of dystrophin, a
protein mainly expressed in striated muscle cells.2 The main clinical
manifestations of dystrophinopathies are loss of skeletal and cardiac
muscle strength and elasticity and respiratory insufficiency.3 Cardio-
myopathies are observed in 90% of dystrophic patients, and 20%
die from cardiac complications.4 Dystrophin, a 427 kDa cytoskeletal
protein, plays a major structural role in muscle cells. It links the cytos-
keleton to the extracellular matrix through the binding of the
N-terminus to actin and the C-terminus to the glycoprotein
complex at the sarcolemma, forming a dystrophin multi-protein
complex (DMC).5 The mdx mouse, which lacks dystrophin, is the clas-
sical animal model of DMD.6 The phenotype of mdx mice, however,
does not fully mimic that of dystrophic patients. Contrary to human
carriers of mutations causing full length dystrophin deletions, mdx
mice have a nearly normal lifespan and display different patterns of
distribution and severity of fibrosis.7 Utrophin, a homologue of dys-
trophin encoded by an autosomic gene, is up-regulated in dystrophic
muscle, which may partially compensate for the lack of dystrophin in
mdx mice, providing an explanation to their milder phenotype.8
Similar to dystrophin, utrophin is a member of the DMC and binds
to syntrophins,9 which are adapter proteins between different com-
ponents of the DMC.10 Syntrophins have been shown to mediate
the link between the cardiac voltage-gated sodium channel Nav1.5
and dystrophin.11,12 The Nav1.5 channel plays a key role in the
depolarization phase of the cardiac action potential (AP) as well as
the propagation of the electrical impulse.13 The primordial role of
Nav1.5 for normal cardiac function is emphasized by hundreds of
mutations found in its gene (SCN5A), which have been linked to
cardiac diseases such as type-3 long QT syndrome, Brugada syn-
drome, and dilated cardiomyopathy.14 In a previous study,11 our
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group showed that dystrophin plays an important role in the func-
tional expression of the cardiac sodium channel. Nav1.5 protein
levels and the sodium current were decreased in mdx5cv mice, an
alternative mouse strain of mdx which also lacks full length dystrophin.
Tinsley et al.15 were the first to suggest a compensatory role of
utrophin in the absence of dystrophin. In the present study, we inves-
tigated this potential role of utrophin in the regulation of the cardiac
sodium channel in mdx mice. We first describe a syntrophin-mediated
interaction between Nav1.5 and utrophin. Next, mice deficient for
both dystrophin and utrophin [double knockout (DKO)] were used
to assess the role of utrophin in the regulation of Nav1.5 in mice
lacking dystrophin only (mdx). Sodium channel protein levels and
sodium current density (INa) were decreased in DKO mice compared
with mdx mice, which was reflected in a significant slowing of maximal
upstroke velocity of the AP. These results reveal that utrophin plays a
central role in the regulation of Nav1.5 in mdx mice and provide
additional evidence in support of therapeutic strategies aimed at utro-
phin up-regulation in DMD patients.
2. Methods
The investigation conforms with the Guide for the Care and Use of Lab-
oratory Animals published by the US National Institutes of Health (NIH
Publication no. 85-23, revised 1996). All animal handling was performed
with the permission from the Cantonal Veterinary Administration and
according to the Swiss Federal Animal Protection law.
2.1 Animals
C57BL/6Ros-5Cv (mdx5cv), mdx, and their control C57BL/10 mice were
purchased from Jackson Laboratories (Bar Harbor, ME, USA). Control
C57BL/6J mice were purchased from Janvier (Le Genest, St Isle,
France). Mdx/DKO mice were obtained from the group of Pr. K.E.
Davies (University of Oxford, UK). Male mice, 8–10 weeks of age,
were used in this study.
2.2 Western blots
HEK293 cells or homogenized whole mouse heart was lysed in 1.0 mL of
lysis buffer [50 mmol/L HEPES pH 7.4, 150 mmol/L NaCl, 10% glycerol,
1% Triton, 1 mmol/L EGTA supplemented with 10 mmol/L N-ethyl malei-
mide and protease inhibitors (Roche, Basel, Switzerland)]. Protein con-
centrations were determined by performing Bradford assays (Coo
protein dosage kit; Interchim, Montluc¸on, France). About 40 mg of
protein was loaded onto sodium dodecyl sulphate (SDS)–polyacrylamide
gel electrophoresis (PAGE). Protein transfer was performed using the dry
system transfer i-blot from Invitrogen (Basel, Switzerland). Immunoblot-
ting was performed using the snap-id system of Millipore (Zug, Switzer-
land). Detection was achieved using the LICOR systemw, and band
intensity was quantified with Odyssey software (LICOR, Lincoln,
Nebraska, USA). ‘Edge effects’ observed with high-molecular-weight pro-
teins were verified to avoid modifying quantification by loading samples on
different SDS–PAGE gels (homemade or Invitrogen pre-cast gel). Despite
the presence of edge effects on some gels, values of quantification were
unchanged.
2.3 Immunoprecipitation studies
About 1 mg of HEK293 cell lysate was incubated for 2 h at 48C with the
appropriate antibody cross-linked to agarose beads using the direct
immunoprecipitation kit from Pierce (Lausanne, Switzerland), according
to manufacturer’s instructions. The beads were washed three times
with lysis buffer, and the immunoprecipitated fractions were analysed by
western blot.
2.4 Pull-down assays
About 1 mg of total proteinwas added to 50 mg of glutathione S-transferase
(GST)-Nav1.5 C-terminus beads and incubated for 2 h at 48C.After washing
the beads three times with lysis buffer, precipitated proteins were eluted
with sampling buffer (Invitrogen) and analysed by western blot.
2.5 Membrane preparation
Mouse ventricular tissue was homogenized in homogenization buffer con-
taining 50 mmol/L Tris–HCl, pH ¼ 7.5, 150 mmol/L NaCl, 10 mmol/L
N-ethyl maleimide and protease inhibitors (Roche). The homogenate
was centrifuged for 15 min at 1000 g to pellet debris. The supernatant
was collected and centrifuged at 48C for 45 min at 50 000 g. The pellet
was resuspended in the homogenization buffer supplemented with 1%
Triton and analysed by western blot.
2.6 Isolation of mouse ventricular myocytes
Single cardiomyocytes were isolated according to a modified procedure of
established enzymatic methods.11 See Supplementary material online for
details.
2.7 INa recordings
The whole-cell configuration of the patch-clamp technique was used to
record INa, as described previously.
11 Details are available in Supplemen-
tary material online.
2.8 AP recordings
Trains of APs were recorded in the whole-cell configuration of the patch-
clamp technique, elicited at 0.5 Hz with rectangular pulses (5 ms at 125%
threshold) in the current-clamp mode. Resting potential, amplitude,
maximal upstroke velocity (dV/dt)max, and durations at 30, 50, and 90%
repolarization were averaged from each sequence of APs. See Supplemen-
tary material online for details.
2.9 Statistical analyses
Data are represented as mean values+ SEM. Statistical tests applied are
described in the legends of the different experiments.
3. Results
3.1 Nav1.5 interacts with utrophin via
syntrophin proteins
Nav1.5 has been previously shown to interact indirectly with dystro-
phin and the DMC via syntrophin proteins.11 The direct interaction
between Nav1.5 and syntrophins takes place at the last three C-
terminal amino acids (SIV) of Nav1.5, a PDZ domain-binding
motif.12 Utrophin, a homologue protein of dystrophin, is also
present in the DMC16 and was similarly shown to interact with syn-
trophins. We used HEK293 cells to investigate whether an interaction
between Nav1.5 and utrophin exists as they have a robust endogen-
ous expression of utrophin, but not dystrophin (see Supplementary
material online, Figure S1). HEK293 cells were transiently transfected
with wild-type (WT) Nav1.5 or Nav1.5 DSIV, the WT channel with
the three last amino acids deleted. Nav1.5 was immunoprecipitated,
yielding the co-immunoprecipitated fraction with antibodies against
syntrophin and utrophin. We found that both syntrophin and utrophin
interact with the WT channel (Figure 1A) and that these interactions
are abolished when Nav1.5 DSIV is immunoprecipitated. This finding
confirms that the interaction occurs via the SIV motif of Nav1.5. In
addition, utrophin was identified by mass spectrometry in the
co-immunoprecipitated fraction of Nav1.5 from HEK293 cells (data
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not shown), confirming that the utrophin signal detected with the
anti-utrophin antibody is not due to a cross-reaction with a homolo-
gous protein, such as dystrophin. Syntrophin proteins were then
immunoprecipitated, yielding a co-immunoprecipitated fraction
blotted with antibodies against Nav1.5 and utrophin. Interactions
between utrophin and syntrophins as well as those between syntro-
phins and Nav1.5 were confirmed (Figure 1A). Moreover, the
absence of Nav1.5 DSIV in the co-immunoprecipitated fraction of syn-
trophins suggests that there is no direct interaction between Nav1.5
and utrophin when the SIV sequence of the channel is absent. As
shown in Figure 1B, we observed a significant reduction (23+6%)
in the total Nav1.5 DSIV protein level compared with Nav1.5 WT,
suggesting that the interaction between the channel and syntrophin
proteins affects Nav1.5 expression in HEK293 cells. To determine
whether Nav1.5 and utrophin interact in the mouse heart, where
both utrophin and dystrophin are expressed, we used GST fusion pro-
teins containing either the last 66 amino acids of the Nav1.5 C-
terminus or the corresponding Nav1.5 C-terminus deleted for the
SIV motif (Figure 1C). The GST fusion proteins were used to pull-
down interacting proteins from WT C57BL/6J mouse heart lysates.
As shown in Figure 1D, the WT C-terminus of Nav1.5 interacts with
both dystrophin and utrophin in the mouse heart, and these inter-
actions are SIV motif-dependent. These findings suggest that utro-
phin, like dystrophin, may be an in vivo partner of the cardiac
voltage-gated sodium channel Nav1.5.
3.2 Utrophin is up-regulated in the hearts
of mdx5cv dystrophin-deficient mice
Several studies have shown an up-regulation of utrophin in dystrophic
skeletal and cardiac muscle of different species, including the human,
mouse, and hamster.17–19 However, to our knowledge, the possible
up-regulation of utrophin in cardiac muscle of mdx5cv mice had not
yet been investigated. We set out to determine whether utrophin is
up-regulated in the hearts of mdx5cv mice in which the cardiac
sodium channel Nav1.5 protein and current were shown to be
Figure 1 Nav1.5 and utrophin interact indirectly via the direct interaction of the PDZ-domain binding motif (SIV) of the channel and syntrophin
proteins. (A) Left panel: input signals confirm expression of utrophin, Nav1.5 (WT and DSIV), and syntrophins in HEK293 cells. Middle and right
panels: syntrophins and utrophin co-immunoprecipitate with WT Nav1.5, but not with the mutant channel. (B) Fluorescence intensity of Nav1.5
WT and Nav1.5 DSIV, obtained from four different experiments, was quantified with LICOR Odyssey software (**P, 0.01; two-tailed Student’s
t-test). (C) Schematic representation of the two fusion proteins used for the pull-down experiments described in (D) comprising the last 66
amino acids of Nav1.5 with the PDZ domain-binding motif (SIV). DSIV corresponds to the last 63 amino acids carrying the S2014stop mutation.
(D) Western blots of pull-down fractions performed on mouse ventricular lysates against utrophin and dystrophin. The bottom panel shows a
Ponceau staining of a representative nitrocellulose membrane, showing the presence of GST fusion proteins for different pull-down experiments.
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reduced.11 Western blot experiments show that mdx5cv mice exhibit
an up-regulation of utrophin, as illustrated in Figure 2A. A 52+9%
increase in utrophin expression was found in mdx5cv heart lysates
(Figure 2B), similar to that found in mdx mice compared with
C57BL/10 mice.20 A down-regulation of syntrophin by 28+ 10%
was concomitantly observed in mdx5cv mice when compared with
control mice (Figure 2A and B), consistent with other studies
showing that several proteins of the DMC, including syntrophin,
were down-regulated in the absence of dystrophin.21
3.3 Sodium current and Nav1.5 protein are
down-regulated in the hearts of DKO mice
Given that utrophin may be a partner of Nav1.5 and is up-regulated in
dystrophin-deficient mice, we assessed the consequence of utrophin
deletion in mdx mice (DKO) on INa. We previously found a 30%
reduction in peak sodium current in cardiomyocytes of mdx5cv
mice.11 To confirm whether a decrease in INa is also present in mdx
mice, we performed patch-clamp experiments in the whole-cell con-
figuration on freshly isolated cardiomyocytes. As shown in Figure 3A
and B, INa peak measured at 230 mV is reduced by 37+6% in
mdx cardiomyocytes compared with the control C57BL/10 mice, con-
firming the common regulatory mechanism of INa between these
different mdx strains. Compared with littermate dystrophin-deficient
mdx mice, a 41+ 5% reduction in INa (Figure 3A and B) was found
in DKO mice, representing a 63+ 3% decrease in INa when compared
with C57BL/10 control mice (Figure 3A and B). The difference in the
peak INa between the three groups was accompanied by small but
statistically significant changes in the voltage dependence of activation
and steady-state inactivation (Figure 3C and Table 1). Quantification of
Nav1.5 protein levels by western blot in ventricular lysates of DKO
and mdx mice revealed a statistically significant decrease in Nav1.5
(25+ 8%) in DKO mice compared with mdx littermates (Figure 4A
and B), providing a potential explanation for the decrease in INa.
The amount of sodium channel proteins was also compared in mem-
brane fractions from C57BL/10, mdx, and DKO hearts (Figure 4C).
These experiments confirmed the statistically significant decrease in
Nav1.5 protein levels between C57BL/10 and mdx (17+4%) and
also between mdx and DKO (14+7%). The decrease in the
sodium channel in ventricular lysates was accompanied by a compar-
able reduction (42+12%) in syntrophin in DKO mice compared with
mdx mice, illustrating the consequences of disorganization of the
DMC on syntrophin expression (Figure 4A and B).
3.4 Maximal AP upstroke velocity is
reduced in DKO compared with mdx
cardiomyocytes
Nav1.5 plays a key role in the conduction of the cardiac electrical
impulse and determines the upstroke velocity (dVm/dt) of the
cardiac AP. Considering the strong reduction in the Nav1.5 protein
and current in DKO compared with mdx mice, we investigated
whether these alterations were reflected in the APs recorded in
freshly isolated ventricular myocytes from these two groups
(Figure 5A). When analysing the AP upstrokes above threshold
(Figure 5B), we found a significant reduction of about 30% in the
maximal upstroke velocity in DKO cardiomyocytes compared with
mdx (110.6+9.2 mV/ms in DKO and 151.8+ 9.4 mV/ms in mdx,
Figure 5C), consistent with the reduction in functional Nav1.5
protein. As shown in Figure 5D and E, no difference was found in
either resting potential (270.6+0.8 and 272.2+0.5 mV in DKO
and mdx, respectively) or AP amplitude (118.1+2.5 and 120.9+
2.1 mV in DKO and mdx, respectively). Finally, although AP durations
of 30 and 50% repolarization (APD30 and APD50) were unchanged,
APD90 was slightly prolonged in DKO mice, although this difference
was not significant (Figure 5F).
4. Discussion
In the present study, we observed that (i) utrophin indirectly binds to
Nav1.5 and this interaction is dependent on the binding of the C-
terminal PDZ-binding domain motif SIV of the channel to syntrophins;
(ii) utrophin is up-regulated in cardiac muscle of mdx5cv mice;
(iii) cardiac sodium channel protein levels and current densities are
strongly reduced in DKO mice compared with mdx mice; and (iv)
Figure 2 Utrophin is up-regulated in the hearts of mdx5cv mice. For comparison of the amounts of utrophin as well as syntrophin present in the
hearts of control and mdx5cv mice, 40 mg of ventricular lysates was loaded on SDS–PAGE gels. The protein concentration of each lysate was
measured in triplicate by Bradford assays to guarantee equivalent loading and confirmed by Ponceau coloration and western blots against actin.
(A) Representative western blots performed with the indicated antibodies. (B) The amount of utrophin and syntrophins examined was assessed
by fluorescence intensity quantification with LICOR Odyssey software (n ¼ 7; *P, 0.05, ***P, 0.001; two-tailed Student’s t-test).
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loss of Nav1.5 in DKO mice leads to slowing of the cardiac AP
upstroke velocity.
4.1 Nav1.5 and utrophin belong to the same
multi-protein complex
The interaction between the cardiac voltage-gated sodium channel
Nav1.5 and syntrophin proteins has been described in previous
studies.11,12 We demonstrated that this interaction occurs via the
PDZ domain-binding motif (SIV) of Nav1.5 and syntrophins.
11 There
are five members (a1, b1, b2, g1, and g2) of the syntrophin family
that are differentially distributed in skeletal muscle and other
tissues.22,23 In the heart, only three members have been found to
be expressed,24 with an unknown distribution. Gavillet et al.11
observed that a1, b1, and b2 syntrophin may be partners of Nav1.5
in vivo. Syntrophins are recognized as adapter proteins, linking
Figure 3 INa is decreased in mdx and DKO cardiomyocytes. (A) Representative traces of whole-cell currents recorded in cardiomyocytes of control,
mdx, and DKO mice, showing that INa is reduced in the absence of dystrophin, and significantly more when utrophin is also lacking. (B) Normalized
current density–voltage (IV) relationships of INa in control, mdx, and DKO mice. The voltage protocol is indicated in the inset [*P, 0.05, **P, 0.01,
***P, 0.001 vs. C57BL/10; }P, 0.05, }}P, 0.01, }}}P, 0.001 vs. mdx; one-way analysis of variance (ANOVA) followed by a Bonferroni’s multiple
comparison test]. (C) Activation and steady-state inactivation (SSI) curves in control, mdx, and DKO cardiomyocytes, with corresponding Boltzmann
fits.
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membrane and membrane-associated proteins to the DMC by binding
to the C-terminus of dystrophin. The primary structures of the
C-terminus of utrophin and dystrophin are very similar,25 and there
is evidence from in vitro and in vivo studies that utrophin can also inter-
act with members of the DMC, such as b-dystroglycan,
a-dystrobrevin-1, and syntrophins.26,27 In the heart, however, evi-
dence of an utrophin-associated complex at the cellular or subcellular
level has not yet been identified. We obtained evidence that utrophin,
similar to dystrophin, could be an in vivo partner of Nav1.5, even
though we failed to demonstrate it in the mouse heart by
co-immunoprecipitation experiments, despite testing many different
protocols. We also showed that this indirect interaction is dependent
on the direct interaction of the SIV domain of the channel with syn-
trophin. Although utrophin localization has been well characterized
at the neuromuscular junction (NMJ),28 very little is known about
its cardiac subcellular localization and different studies published are
controversial.29–31 The generation of two different strains of
Figure 4 Nav1.5 and syntrophin protein levels are decreased in the hearts of DKO mice. For comparison of the amounts of Nav1.5 and syntrophin
present in the hearts of mdx and DKO mice, 40 mg of ventricular lysates was loaded on SDS–PAGE gels. The protein concentration of each lysate was
measured in triplicate by Bradford assays to guarantee equivalent loading and confirmed by Ponceau coloration and western blot against actin.
(A) Representative western blots performed with the indicated antibodies. (B) The amount of Nav1.5 and syntrophins was assessed by fluorescence
intensity quantification with LICOR Odyssey software (n ¼ 6; **P, 0.01; two-tailed Student’s t-test). (C) Nav1.5 protein level in membrane fractions
from C57BL/10, mdx, and DKO mice. Upper panel: representative western blot anti-Nav1.5 of membrane preparation; lower panel: Ponceau-S color-
ation showing a similar protein loading under different conditions. Right panel: bar graph representing quantification of Nav1.5 in membrane prep-
aration of the different genotypes indicated. Number of mice used is indicated in the bar graph. Statistical significance was tested using a one-way
ANOVA followed by a Newman–Keuls multiple comparison test (**P, 0.01 and *P, 0.05).
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Table 1 Voltage dependence of activation and
inactivation properties of isolated ventricular
cardiomyocytes from DKO, mdx, and C57BL/10 mice
C57BL/10 Mdx DKO
Activation n ¼ 9 n ¼ 9 n ¼ 16
K (mV) 4.9+0.2 4.9+0.2 4.5+0.2
V1/2 (mV) 243.5+0.7 239.5+0.4
a 236.9+0.8b
Inactivation n ¼ 9 n ¼ 9 n ¼ 16
K (mV) 6.3+0.1 6.7+0.2 6.6+0.2
V1/2 (mV) 288.2+1.3 282.9+1.0
a 279.6+0.7b
One-way ANOVA with Bonferroni post-test.
aP, 0.01 vs. WT mice.
bP, 0.05 vs. mdx mice.
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utrophin-deficient mice has revealed very subtle phenotypes at the
NMJ,32,33 without any evidence of dystrophin up-regulation.
However, recent studies in vascular endothelial cells suggest that
utrophin could be essential for the assembly of the DMC.34 Although
utrophin may play a minor role in the integrity of the DMC and the
expression of functional Nav1.5 in striated muscle where dystrophin
is normally abundant, our results suggest that it could be important
in tissues where the composition of the DMC is altered, for instance
when dystrophin is absent because mutation of its gene, or decreased
in failing hearts.35
4.2 Utrophin up-regulation in hearts of
mdx5cv mice
The mdx mouse is the most widely used animal model for DMD.
The mdx mouse lacks dystrophin as a result of a point mutation in
exon 23 of the dystrophin gene, forming a premature stop codon.36
However, ‘revertant’ dystrophin-positive cells have been reported
in these mice.37 The mdx5cv mouse, generated by N-ethyl
N-nitrosourea mutagenesis, also lacks full length dystrophin and
does not display revertant cells. Cardiac up-regulation of utrophin
has been reported in different animal models lacking full length dys-
trophin, such as human, hamster, and the mdx mouse,17–19 but utro-
phin over-expression in the hearts of mdx5cv mice has not been
previously reported. We provide evidence that the up-regulation of
utrophin also occurs in mdx5cv mice. In order to verify that the
decrease in functional Nav1.5 found in mdx5cv was not strain-specific,
we assessed the sodium peak current in mdx mice. We found a
decrease similar to that previously observed in mdx5cv,11 suggesting
that down-regulation of the channel in the absence of dystrophin is
a general phenomenon in mice and occurs despite utrophin
over-expression.
Figure 5 AP upstroke velocity is reduced in DKO mice. (A) Representative APs recorded from the cardiomyocytes of mdx and DKO mice. (B) AP
upstrokes from (A) displayed on expanded time-scale reveal a slowing of depolarization velocity above threshold. (C) Maximal AP upstroke velocity is
reduced by 30% in cardiomyocytes from DKO (black bar) compared with mdx mice (white bar). Neither resting potential (D) nor AP amplitude
(E) was different between DKO and mdx cardiomyocytes. (F ) Bar graph showing AP duration to 30, 50, and 90% repolarization in mdx and DKO
cardiomyocytes. n ¼ 12 cells (mdx) and 10 cells (DKO), respectively. **P, 0.01; two-tailed Student’s t-test.
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4.3 Consequences of decreased Nav1.5
protein and sodium current in DKO mice
We found that deletion of the SIV motif of Nav1.5, abolishing its inter-
action with the syntrophin proteins, leads to a decrease in the
expression of the channel in HEK293 cells. Moreover, we found
that utrophin deletion in mdx mice leads to a strong reduction in
the Nav1.5 protein and sodium peak current. A similar decrease in
syntrophins was concomitantly observed, suggesting that the two pro-
teins may belong to the same complex and have a similar fate in the
absence of dystrophin or utrophin. This observation raises the ques-
tion of the role of the DMC in the stabilization of sodium channels at
the sarcolemma. Further investigations will be needed to determine
whether targeting or anchoring of these two proteins is altered
when dystrophin and utrophin are absent. DKO mice are considered
to be a more appropriate model of human dystrophies than mdx mice
as they display most of the clinical signs of DMD, including short
stature, kyphosis, hindlimb weakness, laboured breathing, and prema-
ture death.36 In addition, cardiac complications in DKO mice are
similar to those seen in DMD patients. DKO mice exhibit abnormal
ECG patterns with drastically decreased S-to-R wave ratios, a
feature observed in 70–80% of the DMD patients.38,39 However, con-
duction defects have not been reported as a prominent feature
neither in DKO mice nor in DMD patients. As conduction defects
are progressive in DMD40 and in SCN5A-related animal models41,42
despite an important decrease in INa from birth on, one may speculate
that the age-dependent conduction defect phenotypes observed in
sodium-channel-related pathologies are the result of subsequent
remodelling processes involving fibrotic changes and connexin pro-
teins remodelling as observed by van Veen et al.43 In the present
study, we found a 40% decrease in the peak sodium current in the car-
diomyocytes of DKO mice when compared with mdx mice. Similar to
results obtained by Leoni et al.,42 we also observed that the loss of
Nav1.5 proteins and current promotes significant shifts towards
more positive voltages of steady-state inactivation and activation
curves, increasing the fraction of sodium channels available for
cardiac depolarization in DKO mice when compared with mdx
mice. Molecular and cellular mechanisms altering the biophysical
properties of Nav1.5 when channel quantity is decreased remain to
be investigated. The strong reduction in the sodium current of
DKO cardiomyocytes is reflected by a significant slowing of the AP
maximal upstroke velocity, considered as a suitable index for the esti-
mation of available functional sodium channels. The maximal upstroke
velocity has been shown to slightly overestimate peak INa at slowed
AP upstrokes,44 consistent with the relative decreases in INa and
(dV/dt)max in DKO cardiomyocytes observed in this study. In a pre-
vious study, we have shown that the decrease of 30% in INa observed
in mdx5cv mice compared with C57BL/6J mice is associated with an
increase of 18% of the QRS complex duration in these mice.11 Inter-
estingly, these values are in very good agreement with the predictions
by Shaw and Rudy45 on the influence of reduced maximal sodium
conductance on conduction velocity. Quantitatively, we would esti-
mate that the reduction of another 40% in INa observed in the
present study between mdx and DKO would result in further ventri-
cular conduction slowing of 15–20%. The importantly reduced INa
in DKO hearts thus probably partially underlies the drastic difference
in phenotype between DKO and mdx. However, other proteins such
as inducible nitric oxide synthase or neuronal nitric oxide synthase
have also been shown to be modified in the combined absence of
both dystrophin and utrophin.38 Moreover, cellular pathways known
to be affected in the absence of dystrophin would be expected to
be more severe when utrophin is also absent. For instance, the ampli-
fication of Ca2+- and reactive oxygen species-dependent degradative
pathways in dystrophin-deficient cardiomyocytes46 are most likely
limited by the presence and up-regulation of utrophin in mdx mice
and would thus be expected to contribute to the drastic phenotype
in DKO mice. In conclusion, the difference in phenotype between
mdx and DKO mice is likely the sum of several cellular modifications,
including alteration of the sodium current.
4.4 Relevance for human cardiomyopathies
Different types of cardiomyopathies are the underlying cause of death
in up to 20% of individuals with DMD, a proportion that is likely to
increase over the coming years.4 With ventilatory support preventing
respiratory-related mortality, most DMD patients will survive into
their third decade, in which incidence of cardiomyopathies is nearly
100%.47 We previously reported on the importance of dystrophin
in the regulation of the Nav1.5 protein and its current. In this study,
we demonstrate that the sodium channel phenotype observed in
mdx mice is likely limited by the up-regulation of utrophin. This
suggests that an increased up-regulation of utrophin could, in prin-
ciple, restore more functional sodium channels, supporting current
therapeutic strategies aimed at treating DMDs through the over-
expression of endogenous utrophin.15 Compared with other
approaches such as gene or cell therapy that targets exogenous dys-
trophin expression,48 pharmacological strategies designed to over-
express utrophin are promising and may circumvent many obstacles
inherent to gene and cell-based therapies such as adverse immune
response.49,50 In this study, we provide additional evidence that the
over-expression of utrophin could have a positive outcome in the
absence of dystrophin and could provide a means to treat cardiomyo-
pathy in dystrophic patients by restoring the amount and integrity of
proteins of the DMC, as is the case for Nav1.5.
In summary, our study provides evidence that up-regulation of
utrophin in the hearts of mdx mice counteracts the reduction in
Nav1.5 protein levels and sodium current. Utrophin deletion in
these mice leads to a severe reduction in channel protein expression
and to the subsequent decrease in the sodium peak current ampli-
tude and maximal upstroke velocity of the AP. It is clear that the
regulatory role of utrophin on Nav1.5 may also be mediated by
syntrophin as suggested by its concomitant decrease with the
sodium channel in utrophin-deficient tissue. Altogether, these find-
ings strongly argue in favour of the development of therapeutic
strategies aimed at utrophin up-regulation to treat cardiac altera-
tions in DMD.
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